{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:04:13Z","timestamp":1788318253097,"version":"build-2803163510"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,20]]},"DOI":"10.18632\/oncotarget.11519","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T15:35:45Z","timestamp":1471966545000},"page":"62490-62502","source":"Crossref","is-referenced-by-count":34,"title":["Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma"],"prefix":"10.18632","volume":"7","author":[{"given":"Shang-Yi","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Hsia","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Cheng","family":"Li","sequence":"additional","affiliation":[{"name":"Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"},{"name":"Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woei","family":"Tsay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Je","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Lung","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Anderson","year":"2011","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2015.5","article-title":"Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma","volume":"50","author":"Cho","year":"2015","journal-title":"Bone Marrow Transplantation"},{"key":"3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial)","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Escoda","year":"2007","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"Bayssas","year":"2007","journal-title":"Haematologica"},{"key":"6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clml.2012.08.007","article-title":"Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors","volume":"13","author":"Sharma","year":"2013","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"7","first-page":"330","article-title":"LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens","volume":"94","author":"Kwong","year":"2014","journal-title":"European Journal of Haematology"},{"key":"8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clml.2013.11.009","article-title":"Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs","volume":"14","author":"Penna","year":"2014","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Ghobrial","year":"2015","journal-title":"Immunological Reviews"},{"key":"10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2014.01.002","article-title":"Orchestrating immune check-point blockade for cancer immunotherapy in combinations","volume":"27","author":"Melero","year":"2014","journal-title":"Current Opinion in Immunology"},{"key":"11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.ai.2015.12.002","article-title":"Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers","volume":"130","author":"Fridman","year":"2016","journal-title":"Advances in Immunology"},{"key":"12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Kroger","year":"2014","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Chen","year":"2002","journal-title":"Nature Medicine"},{"key":"14","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Minato","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Quesnel","year":"2007","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Johnson","year":"2011","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Avigan","year":"2011","journal-title":"Journal of Immunotherapy"},{"key":"18","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Hideshima","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"19","doi-asserted-by":"crossref","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sundan","year":"2015","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"crossref","first-page":"e1047580","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow V\u03b39V\u03b42 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Massaia","year":"2015","journal-title":"Oncoimmunology"},{"key":"21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"de Coca","year":"2015","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Anderson","year":"2015","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Devine","year":"2010","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Ogata","year":"2013","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Johnson","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Fest","year":"2014","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"publisher","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"crossref","first-page":"e0137552","DOI":"10.1371\/journal.pone.0137552","article-title":"Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma- a retrospective study","volume":"10","author":"Tien","year":"2015","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-014-2063-7","article-title":"Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma","volume":"93","author":"Tien","year":"2014","journal-title":"Annals of Hematology"},{"key":"31","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.V76.9.1739.1739","article-title":"Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry","volume":"76","author":"Loken","year":"1990","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/annonc\/mdi273","article-title":"Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan","volume":"16","author":"Tien","year":"2005","journal-title":"Annals of Oncology"},{"key":"33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2010.10.005","article-title":"Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines","volume":"56","author":"Zhang","year":"2011","journal-title":"Cytokine"},{"key":"34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3892\/etm.2015.2876","article-title":"Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis","volume":"11","author":"Ma","year":"2016","journal-title":"Experimental and Therapeutic Medicine"},{"key":"35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Young","year":"2016","journal-title":"Cancer Immunology Research"},{"key":"36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Huang","year":"2014","journal-title":"Cellular Immunology"},{"key":"37","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2567.2007.02723.x","article-title":"Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum","volume":"123","author":"Zhang","year":"2008","journal-title":"Immunology"},{"key":"38","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.164.10.5015","article-title":"Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease","volume":"164","author":"Hallett","year":"2000","journal-title":"Journal of Immunology"},{"key":"39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Zhang","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30077","article-title":"PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","author":"Schraml","year":"2016","journal-title":"International Journal of Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Barlogie","year":"2015","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/QAD.0b013e3282f4de23","article-title":"Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands","volume":"22","author":"Altfeld","year":"2008","journal-title":"AIDS"},{"key":"43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Levy","year":"2013","journal-title":"Blood"},{"key":"44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases","volume":"8","author":"Liu","year":"2008","journal-title":"Nature Reviews Immunology"},{"key":"45","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Zannettino","year":"2011","journal-title":"Leukemia"},{"key":"46","article-title":"Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment","author":"Dubovsky","year":"2016","journal-title":"Cancer Research"},{"key":"47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.matbio.2013.10.005","article-title":"Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse","volume":"35","author":"Sanderson","year":"2014","journal-title":"Matrix Biology"},{"key":"48","first-page":"14","article-title":"Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient","volume":"90B","author":"Owen","year":"2016","journal-title":"Cytometry Part B"},{"key":"49","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Choi","year":"2006","journal-title":"FEBS Letters"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:11:34Z","timestamp":1589285494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":49,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2016,9,20]]}},"alternative-id":["11519","27566569"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11519","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]}}}